Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price objective decreased by investment analysts at Cantor Fitzgerald from $290.00 to $205.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald‘s price target would indicate a potential upside of 28.34% from the stock’s current price.
Other analysts also recently issued research reports about the company. Stifel Nicolaus downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $225.00 price target on the stock. in a research note on Thursday, October 29th. Chardan Capital reduced their price objective on Alnylam Pharmaceuticals from $425.00 to $375.00 and set a “buy” rating for the company in a research note on Friday, October 30th. Jefferies Financial Group raised their price objective on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a “hold” rating in a research note on Tuesday, September 8th. Morgan Stanley decreased their target price on Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating for the company in a report on Friday, October 30th. Finally, Barclays cut their price target on shares of Alnylam Pharmaceuticals from $450.00 to $380.00 and set an “overweight” rating on the stock in a report on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $292.57.
View Our Latest Research Report on ALNY
Alnylam Pharmaceuticals Price Performance
Shares of ALNY opened at $159.73 on Tuesday. The firm has a market capitalization of $21.39 billion, a PE ratio of 8.29 and a beta of 0.42. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.48 and a quick ratio of 2.43. Alnylam Pharmaceuticals has a 1-year low of $149.18 and a 1-year high of $479.79. The company’s fifty day moving average price is $217.12 and its 200-day moving average price is $275.05.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.66 by $14.60. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 155.33% and a net margin of 52.85%. The firm’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.90 EPS. On average, equities research analysts predict that Alnylam Pharmaceuticals will post 6.85 EPS for the current year.
Insider Buying and Selling at Alnylam Pharmaceuticals
In related news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. The trade was a 12.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by company insiders.
Institutional Trading of Alnylam Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in the company. Toth Financial Advisory Corp acquired a new stake in Alnylam Pharmaceuticals during the third quarter valued at $25,000. Burkett Financial Services LLC acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $37,000. CoreCap Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 744.4% in the third quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 134 shares during the period. Keating Financial Advisory Services Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $42,000. Finally, Root Financial Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $48,000. 92.97% of the stock is owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.
Further Reading
- Five stocks we like better than Alnylam Pharmaceuticals
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
